Contact
searchSearch
HMP Global
Login

Small-Cell Lung Cancer Specialty Channel

News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/04/2024
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a...
11/04/2024
Oncology
News
Adjuvant Durvalumab Significantly Extends Survival Among Patients With Limited-Stage Small Cell Lung Cancer
10/23/2024
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the...
10/23/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology
Sally Lau, MD
Videos
Tarlatamab Plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung Cancer
10/08/2024
Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
Sally Lau, MD, discusses results...
10/08/2024
Oncology
Conference Coverage
Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer
10/01/2024
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis...
10/01/2024
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
Conference Coverage
Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer
09/09/2024
According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.
According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.
According to phase 1/2 study...
09/09/2024
Oncology
Conference Coverage
Addition of Anlotinb to Durvalumab Maintenance Improved Survival Results Among Patients With Extensive-Stage Small Cell Lung Cancer
09/09/2024
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE...
09/09/2024
Oncology
Conference Coverage
Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer
09/05/2024
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results...
09/05/2024
Oncology
News
Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer
09/04/2024
According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.
According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.
According to extended follow-up...
09/04/2024
Oncology

News

News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/04/2024
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a...
11/04/2024
Oncology
News
Adjuvant Durvalumab Significantly Extends Survival Among Patients With Limited-Stage Small Cell Lung Cancer
10/23/2024
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the...
10/23/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology
Conference Coverage
Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer
10/01/2024
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis...
10/01/2024
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
Conference Coverage
Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer
09/09/2024
According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.
According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.
According to phase 1/2 study...
09/09/2024
Oncology
Conference Coverage
Addition of Anlotinb to Durvalumab Maintenance Improved Survival Results Among Patients With Extensive-Stage Small Cell Lung Cancer
09/09/2024
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE...
09/09/2024
Oncology
Conference Coverage
Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer
09/05/2024
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results...
09/05/2024
Oncology
News
Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer
09/04/2024
According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.
According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.
According to extended follow-up...
09/04/2024
Oncology

Interactive Features

Quiz
Quiz: Standard of Care for Patients With Small Cell Lung Cancer
11/30/2022
What is the current treatment for patients with small cell lung cancer?
What is the current treatment for patients with small cell lung cancer?
What is the current treatment...
11/30/2022
Oncology
Quiz
True or False: Median PFS of patients with SCLC with inflamed tumors receiving ICI and chemotherapy double that of patients with noninflamed tumors.
11/09/2022
According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?
According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?
According to a retrospective...
11/09/2022
Oncology
Quiz
True or False: PD-1 and PD-L1 inhibitors can be utilized as treatment in almost all stages of small-cell lung cancer (SCLC)?
09/30/2022
Can PD-1 and PD-L1 inhibitors be used to treat small-cell lung cancer in addition to non-small cell lung cancer?
Can PD-1 and PD-L1 inhibitors be used to treat small-cell lung cancer in addition to non-small cell lung cancer?
Can PD-1 and PD-L1 inhibitors be...
09/30/2022
Oncology
Quiz
Quiz: Durvalumab Plus Concurrent Chemoradiation Among PD-L1 Positive Patients With SCLC
08/29/2022
Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...
Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...
Among patients with...
08/29/2022
Oncology
Quiz
Quiz: Current First-Line Standard of Care for Extensive-Stage SCLC
07/25/2022
What treatment option in addition to platinum-based chemotherapy has become the current standard of care in the first-line setting for patients with extensive-stage small-cell lung cancer?
What treatment option in addition to platinum-based chemotherapy has become the current standard of care in the first-line setting for patients with extensive-stage small-cell lung cancer?
What treatment option in...
07/25/2022
Oncology
Quiz
Quiz: Does Next-Generation BAP1 Therapy Inhibit SCLC Cell Viability and Tumor Growth?
07/20/2022
According to study findings, does the recently developed therapy targeting SCLC BAP1 activity iBAP-II inhibit SCLC cell viability and tumor growth in vivo?
According to study findings, does the recently developed therapy targeting SCLC BAP1 activity iBAP-II inhibit SCLC cell viability and tumor growth in vivo?
According to study findings,...
07/20/2022
Oncology
Quiz
Quiz: Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease
07/14/2022
According to systemic review and meta-analysis, when does stereotactic radiosurgery not prolong overall survival compared to whole brain radiotherapy in treatment of patients with small-cell lung cancer and intracranial metastatic disease?
According to systemic review and meta-analysis, when does stereotactic radiosurgery not prolong overall survival compared to whole brain radiotherapy in treatment of patients with small-cell lung cancer and intracranial metastatic disease?
According to systemic review and...
07/14/2022
Oncology
Quiz
Quiz: Which Combination Improved Overall Survival Among Patients With SCLC in the CAPSTONE-1 Trial?
05/24/2022
Findings from the CAPSTONE-1 trial found that the addition of which of the following drugs to chemotherapy significantly improved overall survival in patients with extensive-stage SCLC?
Findings from the CAPSTONE-1 trial found that the addition of which of the following drugs to chemotherapy significantly improved overall survival in patients with extensive-stage SCLC?
Findings from the CAPSTONE-1...
05/24/2022
Oncology
Test Your Knowledge
Quiz: Do Functional Biomarkers Play a Vital Role in SCLC Therapy?
02/24/2022
True or false: Discovering and targeting functional biomarkers for SCLC is crucial in understanding the molecular basis underlying tumorigenesis to better assist in improving clinical treatment.
True or false: Discovering and targeting functional biomarkers for SCLC is crucial in understanding the molecular basis underlying tumorigenesis to better assist in improving clinical treatment.
True or false: Discovering and...
02/24/2022
Oncology
Test Your Knowledge
Quiz: Which Additional Therapy Improves Chemotherapy Experience in Previously Treated ES-SCLC?
02/18/2022
Which of the following treatments are administered to patients with previously treated ES-SCLC, prior to topotecan, to improve the experience of receiving chemotherapy?
Which of the following treatments are administered to patients with previously treated ES-SCLC, prior to topotecan, to improve the experience of receiving chemotherapy?
Which of the following...
02/18/2022
Oncology

Recent News

News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/04/2024
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a...
11/04/2024
Oncology
News
Adjuvant Durvalumab Significantly Extends Survival Among Patients With Limited-Stage Small Cell Lung Cancer
10/23/2024
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the...
10/23/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology
Conference Coverage
Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer
10/01/2024
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis...
10/01/2024
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
Conference Coverage
Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer
09/09/2024
According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.
According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.
According to phase 1/2 study...
09/09/2024
Oncology
Conference Coverage
Addition of Anlotinb to Durvalumab Maintenance Improved Survival Results Among Patients With Extensive-Stage Small Cell Lung Cancer
09/09/2024
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE...
09/09/2024
Oncology
Conference Coverage
Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer
09/05/2024
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results...
09/05/2024
Oncology
News
Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer
09/04/2024
According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.
According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.
According to extended follow-up...
09/04/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use